Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States

Ann Am Thorac Soc. 2020 Dec;17(12):1639-1642. doi: 10.1513/AnnalsATS.202005-574RL.

Authors

Sourya Shrestha¹, Andrea Parriott², Nicolas A Menzies³, Priya B Shete², Andrew N Hill⁴, Suzanne M Marks⁴, David W Dowdy¹

Affiliations

¹ Johns Hopkins Bloomberg School of Public Health Baltimore, Maryland.
² University of California San Francisco San Francisco, California.
³ Harvard T.H. Chan School of Public Health Boston, Massachusetts and.
⁴ Centers for Disease Control and Prevention Atlanta, Georgia.

No abstract available

Publication types

Letter
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Antitubercular Agents / therapeutic use
Drug Therapy, Combination
Humans
Isoniazid
Latent Tuberculosis* / drug therapy
Latent Tuberculosis* / epidemiology
Rifampin / analogs & derivatives
United States / epidemiology

Substances

Antitubercular Agents
Isoniazid
Rifampin
rifapentine

Grants and funding